Final results of the multicenter, open-label, randomized phase II trial PAZOTHYR evaluating continuous versus intermittent administration of pazopanib in radio-iodine-refractory thyroid cancers (NCT01813136).

Christelle De La Fouchardiere,Yann Godbert,Cécile Dalban,Christine Do Cao,Frédéric Illouz,Slimane Zerdoud,Johanna Wassermann,Stéphane Bardet,Patrice Rodien,Cecile N Chougnet,Danielle Benisvy,Patricia Niccoli,Alain Ravaud,William Lebosse,Valérie Bourne-Branchu,Julien Gautier,Sophie Leboulleux,Tuthyref

Final results of the multicenter, open-label, randomized phase II trial PAZOTHYR evaluating continuous versus intermittent administration of pazopanib in radio-iodine-refractory thyroid cancers (NCT01813136).

2020

Christelle De La Fouchardiere
Yann Godbert
Cécile Dalban
Christine Do Cao
Frédéric Illouz
Slimane Zerdoud
Johanna Wassermann
Stéphane Bardet
Patrice Rodien
Cecile N Chougnet
Danielle Benisvy
Patricia Niccoli
Alain Ravaud
William Lebosse
Valérie Bourne-Branchu
Julien Gautier
Sophie Leboulleux
Tuthyref

6540Background: Multikinase inhibitors (MKI) targeting angiogenesis, including pazopanib (P), have shown efficacy in progressive radioiodine refractory thyroid cancers (RAIR-TC) but are accompanied...

Keywords:

Urology
Thyroid
Pazopanib
Refractory
radio iodine
Pathology
open label
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations